Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.
about
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaeditThe clinical efficacy of artemether/lumefantrine (Coartem)Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malariaArtemisinin-based combination therapy for treating uncomplicated malariaThe effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient dataAntimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertaintiesPolymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan ChildrenGametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient dataSelection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina FasoTemporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in UgandaThe use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malariaEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquineTherapeutic Efficacy of Artemether-Lumefantrine (Coartem®) in Treating Uncomplicated P. falciparum Malaria in Metehara, Eastern Ethiopia: Regulatory Clinical StudyMalaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts.Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.Analysis of an ordinal outcome in a multicentric randomized controlled trial: application to a 3- arm anti- malarial drug trial in CameroonMethods for evaluating delivery systems for scaling-up malaria control intervention.Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina FasoDoes the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine?Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved ToolLongitudinal study on Plasmodium falciparum gametocyte carriage following artemether-lumefantrine administration in a cohort of children aged 12-47 months living in Western Kenya, a high transmission areaComparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan childrenA review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmissionIncreased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eliminationCost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania.A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.Malaria: an update on current chemotherapy.In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter geneEfficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire.Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malariaComparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic reviewPharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infantsMultinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens.
P2860
Q21032449-7DFECFBB-18F9-45C5-88B9-19429CB7F61FQ21034141-16F0A074-05AC-40E4-B064-9DB5AFFE284DQ24201077-E12EC6AE-E5E3-4E4F-B6C5-6D0CADBE4275Q24241785-D5ED7C42-28C0-4770-A11E-16EA0355E9FBQ26822489-35C75775-0986-4AFC-A175-8C285EE3C82EQ26866187-905FFC1A-59AA-490F-8662-C1C3368EF55DQ27861962-670ADE2F-AB24-42D4-980D-C51128AE9908Q28068072-41CCC399-0185-4FC0-9718-113580BDDF65Q28125901-81E2966D-05B6-4186-AB49-3FE9D55BD638Q28125904-C5FE0351-D73F-46D8-84B8-86962EDB766EQ28478579-6670AE08-4B81-4314-88E5-078E90E0EA2AQ28542034-51BC2602-EFFD-4522-9B2F-6EA4192D7FF4Q28551712-49CD0301-32A2-472F-B7C5-45FD0836A8EBQ30226671-09ED50DC-9BE4-4312-A5F3-57FAB51DCB15Q33516563-19DD0848-C457-46E3-8898-2DF3536B81E0Q33611095-9B218C14-BBD6-40BB-ABE5-E26EBEF6BEFBQ33623072-A370B593-CF2E-4444-A049-7B972E72C7B4Q33635019-3E9899E9-6615-4B1C-8F2B-D8F1E74DEC4AQ33678483-973A85F3-7DC2-4652-A0F5-7BD2DA500194Q33826359-08E0D133-E879-4FD4-B0CE-319FF5108F94Q33874069-280FE6C4-C02B-4CBF-B5D9-B8E2E68F36A7Q33875677-54E08DA1-6858-43F1-8C70-740037043DC8Q33928116-91BDD43B-A2BD-4B4F-B181-F7225F93265DQ33947834-425EDB05-55E4-4056-97CD-DFFF244FE6CBQ34020818-A12C298C-969B-4B06-AC34-D3245AF6BD88Q34160147-C613A974-2949-467F-8AD7-54BF1FDF2D05Q34177472-0A75B415-63DC-4C55-BA46-D17B5B647261Q34227179-3BDF2079-814E-493E-8FAB-B73E4EC01EBCQ34341784-FA193153-96A2-4A20-8CC8-66DCE5B5D2DEQ34433106-697D2BF3-CFD2-4D71-8478-B5EBA8D62414Q34478084-871D8A13-2F90-4F32-A91B-C6E4A8153278Q34562333-0569664E-21F2-443B-BDD4-3ADBC841621DQ34611124-5D717AF2-BFA4-4C0B-A51F-8E0020EE3AEFQ34629332-DB0A634F-232C-49AF-9EC9-4AD9308DAF95Q34923315-F73B2B07-D2A1-4B1C-8C5C-9EA30D4084A5Q35004867-B651F9CB-0745-481E-9CC8-A65D517E738CQ35029488-BC4BAE03-9A38-4B96-A7D1-E73FD5A9CF78Q35055212-498AE47C-0491-4DE8-B824-D1ADD2A2F633Q35068138-E75F1823-E33A-47F3-A314-50AF4F3D35BCQ35097323-DFDF5766-DB8C-464B-B34E-02D067902E70
P2860
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Artemether-lumefantrine versus ...... ial to guide policy in Uganda.
@ast
Artemether-lumefantrine versus ...... ial to guide policy in Uganda.
@en
type
label
Artemether-lumefantrine versus ...... ial to guide policy in Uganda.
@ast
Artemether-lumefantrine versus ...... ial to guide policy in Uganda.
@en
prefLabel
Artemether-lumefantrine versus ...... ial to guide policy in Uganda.
@ast
Artemether-lumefantrine versus ...... ial to guide policy in Uganda.
@en
P2093
P2860
P50
P1433
P1476
Artemether-lumefantrine versus ...... ial to guide policy in Uganda.
@en
P2093
Adoke Yeka
Ambrose Talisuna
Hasifa Bukirwa
John Bosco Rwakimari
Myers Lugemwa
P2860
P356
10.1371/JOURNAL.PONE.0002390
P407
P577
2008-06-11T00:00:00Z